TORONTO, ONTARIO–(Marketwire – May 10, 2011) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Biophysics Ltd today announced that Arch scientists have reported details of their new technology development at the University of Alberta in the field of biophysics.
Press Releases
Arch Cancer Therapeutics’ Technology Update
TORONTO, ONTARIO–(Marketwire – April 11, 2011) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Cancer Therapeutics (“ACT”) today announced Arch scientists have successfully completed proof of principle studies in the area of targeting brain tumour initiating cells.